CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM syndrome.

MLA

de Wit, Raymond H., et al. “CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM Syndrome.” The Journal of Pharmacology and Experimental Therapeutics, vol. 363, no. 1, Oct. 2017, pp. 35–44. EBSCOhost, https://doi.org/10.1124/jpet.117.242735.

APA

de Wit, R. H., Heukers, R., Brink, H. J., Arsova, A., Maussang, D., Cutolo, P., Strubbe, B., Vischer, H. F., Bachelerie, F., & Smit, M. J. (2017). CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM syndrome. The Journal of Pharmacology and Experimental Therapeutics, 363(1), 35–44. https://doi.org/10.1124/jpet.117.242735

Chicago

de Wit, Raymond H, Raimond Heukers, Hendrik J Brink, Angela Arsova, David Maussang, Pasquale Cutolo, Beatrijs Strubbe, Henry F Vischer, Françoise Bachelerie, and Martine J Smit. 2017. “CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM Syndrome.” The Journal of Pharmacology and Experimental Therapeutics 363 (1): 35–44. doi:10.1124/jpet.117.242735.